ArticleOncogene2026

EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2.

Wanqing Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.